REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedReview

Incretin hormones and type 2 diabetes.

Nauck Michael A, Müller Timo D
Diabetologia2023DOI: 10.1007/s00125-023-05956-x
glucose-dependent insulinotropic polypeptide (GIP)glucagon-like peptide-1 (GLP-1)

Quality Score

7/10

Citations

0

Subjects

Non-Human

Peptide Contacts Analysis

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) in meaningful ways.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Strong methodology makes this a valuable addition to the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) evidence base. The findings here should inform future clinical trial design.

Key Findings

The review highlights the role of incretin hormones GIP and GLP-1 in type 2 diabetes, noting their therapeutic potential through selective agonists or co-agonists to improve glycemic control, cardiorenal outcomes, and body weight.

Limitations

As a review paper, it does not present new primary data but synthesizes existing literature. The conclusions are based on the quality of previous studies which may vary in design and methodology.

How to Interpret This Research

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

4

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Peptide Contacts Analysis

Highlighting the role of incretin hormones in type 2 diabetes and exploring the therapeutic advancements through GLP-1 and GIP agonists.

glucose-dependent insulinotropic polypeptide (GIP)glucagon-like peptide-1 (GLP-1)

Harnessing Incretin Hormones: A New Frontier in Type 2 Diabetes Treatment

Published: May 17, 2026 | Source: Diabetologia (2023) | Category: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1)

Overview

A new review in Diabetologia highlights the critical role of incretin hormones, specifically GIP and GLP-1, in managing type 2 diabetes. The study underscores how these hormones can be harnessed to improve glycemic control, cardiorenal outcomes, and body weight management, offering fresh hope for therapeutic advancements.

Study Background

Incretin hormones are naturally occurring peptides that enhance insulin secretion when blood glucose levels rise after eating. Prior research has shown that in type 2 diabetes, the body's ability to use these hormones effectively is diminished, leading to poor glycemic control and other complications. This review synthesizes existing knowledge on how GIP and GLP-1 function and their therapeutic potential through selective agonists or co-agonists.

What the Research Found

The review found that in type 2 diabetes, the body's response to incretin hormones is compromised. Specifically:

  • GIP: Its ability to stimulate insulin secretion is reduced due to impaired beta cell function or signaling pathway defects.
  • GLP-1: Despite a diminished overall incretin effect, GLP-1 retains its potency in stimulating insulin and suppressing glucagon secretion.

The authors also noted that exogenous GLP-1 can significantly improve fasting and postprandial glucose levels. Additionally, the development of newer drugs like tirzepatide, which acts on both GIP and GLP-1 receptors, shows promise for better glycemic control and additional health benefits such as weight loss.

What This Means for Peptide Users

For individuals using peptides to manage type 2 diabetes, this research suggests that incretin-based therapies could offer enhanced efficacy. The use of selective agonists or co-agonists targeting both GIP and GLP-1 receptors may provide a more comprehensive approach to managing blood sugar levels, cardiorenal health, and weight management.

Limitations and Caveats

As a review paper, this study does not present new primary data but rather synthesizes existing literature. The conclusions are based on the quality of previous studies which can vary widely in design and methodology. Additionally, while promising, the long-term efficacy and safety profiles of newer incretin-based therapies like tirzepatide require further investigation.

How This Compares to Previous Research

This review aligns with earlier research highlighting the importance of GIP and GLP-1 in diabetes management but provides a more nuanced understanding of their roles. It also emphasizes recent advancements in therapeutic options, such as dual-receptor co-agonists, which have not been extensively covered before.

Our Analysis

PeptideVault views this review positively for its comprehensive synthesis of existing literature on incretin hormones and type 2 diabetes. The paper effectively outlines the current understanding of GIP and GLP-1's roles in disease pathophysiology and therapeutic potential. However, it is important to acknowledge that further clinical trials are necessary to validate these findings and establish long-term safety profiles.

Key Takeaways

  • Incretin Hormones: Play a crucial role in regulating blood sugar levels.
  • Therapeutic Potential: GLP-1 agonists and dual-receptor co-agonists show promise for better glycemic control.
  • Future Directions: More research is needed to understand long-term efficacy and safety of incretin-based therapies.

Original Source

Citation: Nauck Michael A, Müller Timo D (2023). Incretin hormones and type 2 diabetes. Diabetologia. DOI: 10.1007/s00125-023-05956-x

Access: https://pubmed.ncbi.nlm.nih.gov/37430117/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was written by the Peptide Contacts research team to make complex findings accessible to the peptide community. We encourage readers to review the source paper for full methodology and data. For more on glucose-dependent insulinotropic polypeptide (GIP), explore our research guides.

Citation

Nauck Michael A, Müller Timo D. (2023). Incretin hormones and type 2 diabetes.. Diabetologia. https://doi.org/10.1007/s00125-023-05956-x

View full text on PubMed

Related Papers

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Mendias Christopher L et al.· Sports medicine (Auckland, N.Z.)· 2026Review

From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management.

Yuan Claire et al.· International journal of molecular sciences· 2026Review

Carbonless amino acids and a carbonless GHK peptide.

Skurski Piotr et al.· Physical chemistry chemical physics : PCCP· 2026Review

The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways.

Wen Huijun et al.· Biogerontology· 2026Review

Glycyl-L-histidyl-L-lysine-Cu2

Hu Jing et al.· European journal of pharmacology· 2026Review

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

Mayfield Cory K et al.· The American journal of sports medicine· 2026Review

Explore Further

Research Library

Browse all indexed papers

Research Guides

Plain-language peptide guides

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.